Sobi to reveal new immunology data at ACR Convergence 2024

WALTHAM, Mass., Nov. 07, 2024 -- Sobi North America, the North American branch of Swedish Orphan Biovitrum AB (Sobi®), has announced the presentation of four abstracts showcasing data from its immunology portfolio at the ACR Convergence 2024 event in Washington, D.C., from November 14–19, 2024. This highlights Sobi’s dedication to developing innovative treatments for immunological diseases through global studies covering multiple disorders.

Key presentations include results from two Phase 3 trials assessing the impact of SEL-212 on patient-reported outcomes in individuals with chronic refractory gout. Additionally, initial findings on how anti-drug antibodies affect serum uric acid (sUA) reduction and safety in response to SEL-212 treatment will be shared. Another significant highlight is the DISSOLVE 1 Phase 3 study, analyzing sustained sUA reduction and safety of SEL-212 for chronic refractory gout patients in the United States. Furthermore, outcomes from a Phase 3 study, along with a pooled analysis of two prospective trials, will present the efficacy and safety of emapalumab in patients with Macrophage Activation Syndrome (MAS) in Still’s disease.

The detailed schedule of key data presentations at the ACR Convergence 2024 is as follows:

**Chronic Refractory Gout SEL-212**
- Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout will be presented during the Patient Outcomes, Preferences, & Attitudes Poster I session on Saturday, November 16, from 10:30 AM to 12:30 PM.
- Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy, and Safety and Efficacy of SEL-212 in the US and ex-US Subgroups: Results from the Phase 3 DISSOLVE Studies will be presented during the Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III session on Monday, November 18, from 10:30 AM to 12:30 PM.

**Macrophage Activation Syndrome Emapalumab**
- The Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s disease will be presented during the Late-Breaking Abstracts session on November 19, from 8:00 AM to 9:30 AM, with the specific presentation from 9:00 AM to 9:15 AM.

All abstracts will be accessible via the official ACR Convergence website.

**About SEL-212**
SEL-212 is under development as a novel once-monthly combination therapy that merges targeted immunomodulation with uricase-based treatment, intended for chronic refractory gout. The drug consists of pegadricase, a proprietary pegylated uricase, co-administered with nanoencapsulated sirolimus.

**About Chronic Refractory Gout**
Gout is the most prevalent form of inflammatory arthritis, affecting over 8.3 million people in the U.S. It is caused by elevated uric acid levels, leading to painful flares. Chronic refractory gout (CRG) affects about 160,000 people in the U.S., characterized by resistance to conventional medications and persistent symptoms. CRG is a severe condition marked by frequent flares and the accumulation of uric acid crystals in tissues.

**About Emapalumab-lzsg**
Emapalumab-lzsg is an anti-IFNγ monoclonal antibody that neutralizes the activity of IFNγ. In the U.S., it is approved for treating pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) who are refractory, recurrent, progressive, or intolerant to conventional HLH therapy. It is the first FDA-approved treatment for primary HLH, a fatal hyperinflammatory syndrome without timely diagnosis and treatment. Emapalumab is administered bi-weekly until hematopoietic stem cell transplantation (HSCT). Its efficacy and safety are currently being evaluated in patients with MAS in Still’s disease and systemic lupus erythematosus (SLE).

**About Sobi North America**
Sobi North America is the North American subsidiary of the international biopharmaceutical company Sobi, committed to providing innovative treatments for rare diseases. With headquarters in the Boston and Toronto areas, the team focuses on immunology, hematology, and specialty care. Sobi employs around 1,800 people globally with a revenue of SEK 22.1 billion in 2023.